Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium

Cancer Research

Volumn 68, Issue 8, 2008, Pages 2861-2869

  Tu, Tianxiang ^a   Thotala, Dinesh ^a   Geng, Ling ^a   Hallahan, Dennis E ^a,b   Willey, Christopher D ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW X KINASE; LFM A13; PHOSPHATIDYLINOSITOL 3 KINASE; POLYPHOSPHOINOSITIDE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL MEMBRANE; CELL MIGRATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; IONIZING RADIATION; IRRADIATION; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIZATION; RETROVIRUS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

AMIDES; BONE MARROW CELLS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; LUNG NEOPLASMS; NITRILES; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; UMBILICAL VEINS;

EID: 42349086371     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5743     Document Type: Article

References (50)

1. Valerie K, Yacoub A, Hagan MP, et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007;6:789-801.
2. Sonveaux P, Frerart F, Bouzin C, et al. Irradiation promotes Akt-targeting therapeutic gene delivery to the tumor vasculature. Int J Radiat Oncol Biol Phys 2007;67: 1155-62.
3. Zingg D, Riesterer O, Fabbro D, Glanzmann C, Bodis S, Pruschy M. Differential activation of the phosphatidylinositol 3′-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells. Cancer Res 2004;64:5398-406.
4. Tan J, Geng L, Yazlovitskaya EM, Hallahan DE. Protein kinase B/Akt-dependent phosphorylation of glycogen synthase kinase-3β in irradiated vascular endothelium. Cancer Res 2006;66:2320-7.
5. Tan J, Hallahan DE. Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response. Cancer Res 2003;63: 7663-7.
6. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 1999;68:965-1014.
7. Chen R, Kim O, Li M, et al. Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain. Nat Cell Biol 2001;3:439-44.
8. Nore BF, Mattsson PT, Antonsson P, et al. Identification of phosphorylation sites within the SH3 domains of Tec family tyrosine kinases. Biochim Biophys Acta 2003; 1645:123-32.
9. Pan S, An P, Zhang R, He X, Yin G, Min W. Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol 2002;22:7512-23.
10. Qiu Y, Kung HJ. Signaling network of the Btk family kinases. Oncogene 2000;19:5651-61.
11. Smith CI, Islam TC, Mattsson PT, Mohamed AJ, Nore BF, Vihinen M. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays 2001;23:436-46.
12. Vargas L, Nore BF, Berglof A, et al. Functional interaction of caveolin-1 with Bruton's tyrosine kinase and Bmx. J Biol Chem 2002;277:9351-7.
13. Yang J, Kim O, Wu J, Qiu Y. Interaction between tyrosine kinase Etk and a RUN domain- and FYVE domain-containing protein RUFY1. A possible role of ETK in regulation of vesicle trafficking. J Biol Chem 2002;277:30219-26.
14. Kaukonen J, Lahtinen I, Laine S, Alitalo K, Palotie A. BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias. Br J Haematol 1996;94:455-60.
15. Mano H. Tec family of protein-tyrosine kinases: an overview of their structure and function. Cytokine Growth Factor Rev 1999;10:267-80.
16. Wen X, Lin HH, Shih HM, Kung HJ, Ann DK. Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells. J Biol Chem 1999;274:38204-10.
17. Chau CH, Clavijo CA, Deng HT, et al. Etk/Bmx mediates expression of stress-induced adaptive genes VEGF, PAI-1, and iNOS via multiple signaling cascades in different cell systems. Am J Physiol Cell Physiol 2005; 289:C444-54.
18. Chau CH, Chen KY, Deng HT, et al. Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation. Oncogene 2002;21: 8817-29.
19. Zhang R, Xu Y, Ekman N, et al. Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem 2003;278:51267-76.
20. Ekman N, Arighi E, Rajantie I, et al. The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner. Oncogene 2000;19:4151-8.
21. Qiu Y, Robinson D, Pretlow TG, Kung HJ. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A 1998;95:3644-9.
22. Cote JF, Motoyama AB, Bush JA, Vuori K. A novel and evolutionarily conserved PtdIns(3,4,5)P3-binding domain is necessary for DOCK180 signalling. Nat Cell Biol 2005;7:797-807.
23. Kim O, Yang J, Qiu Y. Selective activation of small GTPase RhoA by tyrosine kinase Etk through its pleckstrin homology domain. J Biol Chem 2002;277: 30066-71.
24. Lee LF, Guan J, Qiu Y, Kung HJ. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001;21:8385-97.
25. Abassi YA, Rehn M, Ekman N, Alitalo K, Vuori K. p130Cas Couples the tyrosine kinase Bmx/Etk with regulation of the actin cytoskeleton and cell migration. J Biol Chem 2003;278:35636-43.
26. Jui HY, Tseng RJ, Wen X, et al. Protein-tyrosine phosphatase D1, a potential regulator and effector for Tec family kinases. J Biol Chem 2000;275:41124-32.
27. Tomlinson MG, Heath VL, Turck CW, Watson SP, Weiss A. SHIP family inositol phosphatases interact with and negatively regulate the Tec tyrosine kinase. J Biol Chem 2004;279:55089-96.
28. Cuneo KC, Tu T, Geng L, Fu A, Hallahan DE, Willey CD. HIV protease inhibitors enhance the efficacy of irradiation. Cancer Res 2007;67:4886-93.
29. Edwards E, Geng L, Tan J, Onishko H, Donnelly E, Hallahan DE. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 2002;62:4671-7.
30. He H, Hirokawa Y, Gazit A, et al. The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Cancer Biol Ther 2004;3: 96-101.
31. Uckun FM, Zheng Y, Cetkovic-Cvrlje M, et al. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of α-cyano-β-hydroxy-β- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res 2002;8:1224-33.
32. Mahajan S, Ghosh S, Sudbeck EA, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem 1999;274:9587-99.
33. Kawakami Y, Hartman SE, Kinoshita E, et al. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. Proc Natl Acad Sci U S A 1999;96:2227-32.
34. Geng L, Tan J, Himmelfarb E, et al. A specific antagonist of the p110y catalytic component of phosphatidylinositol 3′-kinase, IC486068, enhances radiation-induced tumor vascular destruction. Cancer Res 2004;64:4893-9.
35. Lee CM, Fuhrman CB, Planelles V, et al. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res 2006;12:250-6.
36. Lu B, Shinohara ET, Edwards E, Geng L, Tan J, Hallahan DE. The use of tyrosine kinase inhibitors in modifying the response of tumor microvasculature to radiotherapy. Technol Cancer Res Treat 2005;4:691-8.
37. Paz K, Brennan LA, Iacolina M, Doody J, Hadari YR, Zhu Z. Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Mol Cancer Ther 2005;4:1801-9.
38. Pan Z, Scheerens H, Li SJ, et al. Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase. ChemMedChem 2007;2:58-61.
39. Tsai YT, Su YH, Fang SS, et al. Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Mol Cell Biol 2000;20: 2043-54.
40. Saharinen P, Ekman N, Sarvas K, Parker P, Alitalo K, Silvennoinen O. The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cδ. Blood 1997; 90:4341-53.
41. Zhang J, Ping P, Wang GW, et al. Bmx, a member of the Tec family of nonreceptor tyrosine kinases, is a novel participant in pharmacological cardioprotection. Am J Physiol Heart Circ Physiol 2004;287:H2364-6.
42. Xie Y, Xu K, Dai B, et al. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 2006;25:70-8.
43. Xue LY, Qiu Y, He J, Kung HJ, Oleinick NL. Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin. Oncogene 1999;18:3391-8.
44. Stoletov KV, Terman BI. Bmx is a downstream Rap1 effector in VEGF-induced endothelial cell activation. Biochem Biophys Res Commun 2004;320:70-5.
45. Paavonen K, Ekman N, Wirzenius M, Rajantie I, Poutanen M, Alitalo K. Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing. Mol Biol Cell 2004;15: 4226-33.
46. Mathur P, Kaga S, Zhan L, Das DK, Maulik N. Potential candidates for ischemic preconditioning-associated vascular growth pathways revealed by antibody array. Am J Physiol Heart Circ Physiol 2005;288:H3006-10.
47. Rajantie I, Ekman N, Iljin K, et al. Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol Cell Biol 2001;21: 4647-55.
48. Jiang T, Guo Z, Dai B, et al. Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage. J Biol Chem 2004; 279:50181-9.
49. Dai B, Kim O, Xie Y, et al. Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res 2006;66:8058-64.
50. Bagheri-Yarmand R, Mandal M, Taludker AH, et al. Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J Biol Chem 2001; 276:29403-9.